This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raut, C. P. Articles by Bertagnolli, M. M. Search for Related Content PubMed PubMed Citation Articles by Raut, C. P. Articles by Bertagnolli, M. M. Social Bookmarking                            What's this?

Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors

From the Departments of Surgery, Anesthesia, Medical Oncology, Biostatistics and Computational Biology, and Pathology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Address reprint requests to Monica M. Bertagnolli, MD, Brigham and Women's Hospital, Department of Surgery, 75 Francis St, Boston, MA 02115; e-mail: mbertagnolli{at}partners.org

Purpose While targeted inhibitors of tyrosine kinase activity demonstrate dramatic efficacy in the majority of patients with advanced gastrointestinal stromal tumors (GISTs), cure remains elusive and resistance to systemic therapy is a challenge. To assess the role of surgery in multimodality management of GISTs, we studied postoperative outcomes in patients treated with targeted kinase inhibitors for advanced GIST.

Methods We evaluated outcomes in a single institution series of 69 consecutive patients who underwent surgery for advanced GISTs while receiving kinase inhibitors. Patients were categorized based on extent of disease before surgery (stable disease, limited disease progression, generalized disease progression) and surgical result (no evidence of disease, minimal residual disease, bulky residual disease).

Results Disease status before surgery was associated with surgical result (P < .0001; median follow-up, 14.6 months). After surgery, there was no evidence of disease in 78%, 25%, and 7% of patients with stable disease, limited progression, and generalized progression, respectively. Bulky residual disease remained after surgery in 4%, 16%, and 43% of the patients with stable disease, limited progression, and generalized progression. Twelve-month progression-free survival was 80%, 33%, and 0% for patients with stable disease, limited progression, and generalized progression (P < .0001). Twelve-month overall survival was 95%, 86%, and 0% for patients with stable disease, limited progression, and generalized progression (P < .0001).

Conclusion Patients with advanced GISTs exhibiting stable disease or limited progression on kinase inhibitor therapy have prolonged overall survival after debulking procedures. Surgery has little to offer in the setting of generalized progression.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. G. Casali, L. Jost, P. Reichardt, M. Schlemmer, J.-Y. Blay, and On behalf of the ESMO Guidelines Working Group Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv64 - iv67. [Full Text] [PDF]

				C. P. Raut and R. P. DeMatteo Evidence-Guided Surgical Management of GIST: Beyond a Simple Case of Benign and Malignant Ann. Surg. Oncol., May 1, 2008; 15(5): 1542 - 1543. [Full Text] [PDF]

				C. P. Raut and R. P. DeMatteo Prognostic Factors for Primary GIST: Prime Time for Personalized Therapy? Ann. Surg. Oncol., January 1, 2008; 15(1): 4 - 6. [Full Text] [PDF]

				I. Hassan, Y. N. You, R. Shyyan, E. J. Dozois, T. C. Smyrk, S. H. Okuno, C. D. Schleck, D. O. Hodge, and J. H. Donohue Surgically Managed Gastrointestinal Stromal Tumors: A Comparative and Prognostic Analysis Ann. Surg. Oncol., January 1, 2008; 15(1): 52 - 59. [Abstract] [Full Text] [PDF]

				J. C. McAuliffe, A. J.F. Lazar, D. Yang, D. M. Steinert, W. Qiao, P. F. Thall, A. K. Raymond, R. S. Benjamin, and J. C. Trent Association of Intratumoral Vascular Endothelial Growth Factor Expression and Clinical Outcome for Patients with Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate Clin. Cancer Res., November 15, 2007; 13(22): 6727 - 6734. [Abstract] [Full Text] [PDF]

				K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]

				S. S. Yoon and K. K. Tanabe Should Surgical Resection Be Combined with Imatinib Therapy for Locally Advanced or Metastatic Gastrointestinal Stromal Tumors? Ann. Surg. Oncol., June 1, 2007; 14(6): 1784 - 1786. [Full Text] [PDF]

				F. R. Jamali, S. S. Darwiche, N. El-Kinge, A. Tawil, and A. M. Soweid Disease Progression Following Imatinib Failure in Gastrointestinal Stromal Tumors: Role of Surgical Therapy Oncologist, April 1, 2007; 12(4): 438 - 442. [Abstract] [Full Text] [PDF]

				J.-Y. Blay, A. Le Cesne, I. Ray-Coquard, B. Bui, F. Duffaud, C. Delbaldo, A. Adenis, P. Viens, M. Rios, E. Bompas, et al. Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group J. Clin. Oncol., March 20, 2007; 25(9): 1107 - 1113. [Abstract] [Full Text] [PDF]

				E. Wardelmann, K. Biermann, S. Merkelbach-Bruse, H.-U. Schildhaus, N. Thomas, R. Buttner, T. Pietsch, T. Heinicke, N. Speidel, D. Pink, et al. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. Clin. Cancer Res., October 15, 2006; 12(20): 6206 - 6206. [Full Text] [PDF]